• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性滑膜肉瘤类器官的染色质景观与特定的表观遗传机制和依赖性相关。

The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies.

机构信息

Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

出版信息

Life Sci Alliance. 2020 Dec 23;4(2). doi: 10.26508/lsa.202000808. Print 2021 Feb.

DOI:10.26508/lsa.202000808
PMID:33361335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7768195/
Abstract

Synovial sarcoma (SyS) is an aggressive mesenchymal malignancy invariably associated with the chromosomal translocation t(X:18; p11:q11), which results in the in-frame fusion of the BAF complex gene to one of three genes. Fusion of SS18 to SSX generates an aberrant transcriptional regulator, which, in permissive cells, drives tumor development by initiating major chromatin remodeling events that disrupt the balance between BAF-mediated gene activation and polycomb-dependent repression. Here, we developed SyS organoids and performed genome-wide epigenomic profiling of these models and mesenchymal precursors to define SyS-specific chromatin remodeling mechanisms and dependencies. We show that SS18-SSX induces broad BAF domains at its binding sites, which oppose polycomb repressor complex (PRC) 2 activity, while facilitating recruitment of a non-canonical (nc)PRC1 variant. Along with the uncoupling of polycomb complexes, we observed H3K27me3 eviction, H2AK119ub deposition and the establishment of de novo active regulatory elements that drive SyS identity. These alterations are completely reversible upon SS18-SSX depletion and are associated with vulnerability to USP7 loss, a core member of ncPRC1.1. Using the power of primary tumor organoids, our work helps define the mechanisms of epigenetic dysregulation on which SyS cells are dependent.

摘要

滑膜肉瘤(SyS)是一种具有侵袭性的间叶组织恶性肿瘤,始终与染色体易位 t(X:18;p11:q11)相关,该易位导致 BAF 复合物基因与三个基因之一发生融合。SS18 与 SSX 的融合产生了一个异常的转录调节剂,在允许的细胞中,通过启动主要的染色质重塑事件,破坏 BAF 介导的基因激活和多梳依赖性抑制之间的平衡,从而驱动肿瘤的发展。在这里,我们开发了 SyS 类器官,并对这些模型和间充质前体进行了全基因组表观基因组谱分析,以定义 SyS 特异性染色质重塑机制和依赖性。我们表明,SS18-SSX 在其结合位点诱导广泛的 BAF 结构域,这些结构域与多梳抑制复合物(PRC)2 活性相反,同时促进非典型(nc)PRC1 变体的募集。除了多梳复合物的解偶联外,我们还观察到 H3K27me3 的排出、H2AK119ub 的沉积以及驱动 SyS 特征的新的活性调控元件的建立。在 SS18-SSX 耗尽后,这些改变是完全可逆的,并且与 USP7 缺失相关,USP7 是 ncPRC1.1 的核心成员。利用原发性肿瘤类器官的力量,我们的工作有助于定义 SyS 细胞依赖的表观遗传失调机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/20e51e910e6a/LSA-2020-00808_FigS8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/20e9f40c3717/LSA-2020-00808_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6f9b339b39e1/LSA-2020-00808_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/ac023c0079d2/LSA-2020-00808_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/becbc4dcc0d6/LSA-2020-00808_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/38e26069d180/LSA-2020-00808_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/f99f83019c07/LSA-2020-00808_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/f78439fd260c/LSA-2020-00808_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6bc3f6f62b28/LSA-2020-00808_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/0ad37a8fdf97/LSA-2020-00808_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/3d4b0f2bc386/LSA-2020-00808_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6028f6d07f3f/LSA-2020-00808_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/06f4b1ec0618/LSA-2020-00808_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/01c125fbedf3/LSA-2020-00808_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/9a1b1c0eb0a2/LSA-2020-00808_Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/20e51e910e6a/LSA-2020-00808_FigS8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/20e9f40c3717/LSA-2020-00808_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6f9b339b39e1/LSA-2020-00808_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/ac023c0079d2/LSA-2020-00808_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/becbc4dcc0d6/LSA-2020-00808_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/38e26069d180/LSA-2020-00808_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/f99f83019c07/LSA-2020-00808_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/f78439fd260c/LSA-2020-00808_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6bc3f6f62b28/LSA-2020-00808_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/0ad37a8fdf97/LSA-2020-00808_FigS5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/3d4b0f2bc386/LSA-2020-00808_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/6028f6d07f3f/LSA-2020-00808_Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/06f4b1ec0618/LSA-2020-00808_FigS6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/01c125fbedf3/LSA-2020-00808_FigS7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/9a1b1c0eb0a2/LSA-2020-00808_Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7005/7768195/20e51e910e6a/LSA-2020-00808_FigS8.jpg

相似文献

1
The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies.原发性滑膜肉瘤类器官的染色质景观与特定的表观遗传机制和依赖性相关。
Life Sci Alliance. 2020 Dec 23;4(2). doi: 10.26508/lsa.202000808. Print 2021 Feb.
2
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.SS18-SSX 融合癌蛋白劫持 BAF 复合物靶向和功能以驱动滑膜肉瘤。
Cancer Cell. 2018 Jun 11;33(6):1128-1141.e7. doi: 10.1016/j.ccell.2018.05.002. Epub 2018 May 31.
3
Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.滑膜肉瘤中的异常基因激活依赖于 SSX 的特异性和 PRC1.1 稳定性的增加。
Nat Struct Mol Biol. 2023 Nov;30(11):1640-1652. doi: 10.1038/s41594-023-01096-3. Epub 2023 Sep 21.
4
The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.滑膜肉瘤相关的SS18-SSX2融合蛋白诱导表观遗传基因(去)调控。
Cancer Res. 2006 Oct 1;66(19):9474-82. doi: 10.1158/0008-5472.CAN-05-3726.
5
SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.滑膜肉瘤中的致癌融合蛋白SS18-SSX是一种细胞环境依赖性表观遗传修饰因子。
PLoS One. 2015 Nov 16;10(11):e0142991. doi: 10.1371/journal.pone.0142991. eCollection 2015.
6
Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.滑膜肉瘤:一种具有多方面信号和表观遗传景观的复杂疾病。
Curr Oncol Rep. 2020 Oct 6;22(12):124. doi: 10.1007/s11912-020-00985-w.
7
Synovial sarcoma: when epigenetic changes dictate tumour development.滑膜肉瘤:当表观遗传变化决定肿瘤发展时。
Swiss Med Wkly. 2018 Dec 2;148:w14667. doi: 10.4414/smw.2018.14667. eCollection 2018 Nov 19.
8
Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.滑膜肉瘤中 SS18-SSX 致癌融合导致 mSWI/SNF(BAF)复合物的可逆破坏。
Cell. 2013 Mar 28;153(1):71-85. doi: 10.1016/j.cell.2013.02.036.
9
Genome-wide recruitment to Polycomb-modified chromatin and activity regulation of the synovial sarcoma oncogene SYT-SSX2.全基因组募集到多梳修饰染色质和滑膜肉瘤致癌基因 SYT-SSX2 的活性调节。
BMC Genomics. 2012 May 17;13:189. doi: 10.1186/1471-2164-13-189.
10
Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.滑膜肉瘤:作为新治疗途径路线图的最新发现
Cancer Discov. 2015 Feb;5(2):124-34. doi: 10.1158/2159-8290.CD-14-1246. Epub 2015 Jan 22.

引用本文的文献

1
Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatment.滑膜肉瘤中的分子与表观遗传致癌作用:对癌症生物学、诊断及治疗的意义
Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03547-1.
2
Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis.靶向SUMO2可逆转由SS18::SSX融合癌蛋白驱动的异常表观遗传重编程,并损害肉瘤发生。
EMBO J. 2025 Aug 13. doi: 10.1038/s44318-025-00526-w.
3
Synovial organoids: From fundamental construction to groundbreaking applications in arthritic disorders.

本文引用的文献

1
Interaction between Polycomb and SSX Proteins in Pericentromeric Heterochromatin Function and Its Implication in Cancer.聚蛋白和 SSX 蛋白在着丝粒异染色质功能中的相互作用及其在癌症中的意义。
Cells. 2020 Jan 16;9(1):226. doi: 10.3390/cells9010226.
2
Epigenetic Targets in Synovial Sarcoma: A Mini-Review.滑膜肉瘤中的表观遗传靶点:一篇综述短文
Front Oncol. 2019 Oct 18;9:1078. doi: 10.3389/fonc.2019.01078. eCollection 2019.
3
Human Organoids: Tools for Understanding Biology and Treating Diseases.人类类器官:理解生物学和治疗疾病的工具。
滑膜类器官:从基础构建到在关节炎疾病中的突破性应用
J Orthop Translat. 2025 Jul 16;54:26-36. doi: 10.1016/j.jot.2025.07.004. eCollection 2025 Sep.
4
Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group.肉瘤患者来源的3D体外模型的建立:代表FORTRESS工作组的文献综述与指南
Neoplasia. 2025 Jul;65:101171. doi: 10.1016/j.neo.2025.101171. Epub 2025 May 3.
5
Self-assembled patient-derived tumor-like cell clusters for personalized drug testing in diverse sarcomas.用于多种肉瘤个性化药物测试的自组装患者来源肿瘤样细胞簇
Cell Rep Med. 2025 Mar 18;6(3):101990. doi: 10.1016/j.xcrm.2025.101990. Epub 2025 Mar 6.
6
Global Literature Analysis of Tumor Organoid and Tumor-on-Chip Research.肿瘤类器官和芯片上肿瘤研究的全球文献分析
Cancers (Basel). 2025 Jan 1;17(1):108. doi: 10.3390/cancers17010108.
7
SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis.SUMO2抑制可逆转滑膜肉瘤融合癌蛋白驱动的异常表观遗传重编程并损害肉瘤发生。
bioRxiv. 2024 Sep 25:2024.09.23.614593. doi: 10.1101/2024.09.23.614593.
8
Differential modulation of polycomb-associated histone marks by cBAF, pBAF, and gBAF complexes.多梳相关组蛋白标记的 cBAF、pBAF 和 gBAF 复合物的差异调节。
Life Sci Alliance. 2024 Aug 29;7(11). doi: 10.26508/lsa.202402715. Print 2024 Nov.
9
Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.组蛋白去乙酰化酶(HDAC)抑制剂与FYN抑制剂联合用于滑膜肉瘤治疗
Front Cell Dev Biol. 2024 Jul 9;12:1422452. doi: 10.3389/fcell.2024.1422452. eCollection 2024.
10
Biological and therapeutic insights from animal modeling of fusion-driven pediatric soft tissue sarcomas.融合驱动型儿科软组织肉瘤动物模型的生物学和治疗学见解。
Dis Model Mech. 2024 Jun 1;17(6). doi: 10.1242/dmm.050704. Epub 2024 Jun 25.
Annu Rev Pathol. 2020 Jan 24;15:211-234. doi: 10.1146/annurev-pathmechdis-012419-032611. Epub 2019 Sep 24.
4
Cancer modeling meets human organoid technology.癌症建模与人类类器官技术相遇。
Science. 2019 Jun 7;364(6444):952-955. doi: 10.1126/science.aaw6985.
5
Is it time to take R(epressive) out of PRC1?是否该将 R(epressive)从 PRC1 中去除?
Genes Dev. 2019 Jan 1;33(1-2):4-5. doi: 10.1101/gad.322651.118.
6
PRC1 preserves epidermal tissue integrity independently of PRC2.PRC1 独立于 PRC2 维持表皮组织完整性。
Genes Dev. 2019 Jan 1;33(1-2):55-60. doi: 10.1101/gad.319939.118. Epub 2018 Dec 19.
7
Synovial sarcoma: when epigenetic changes dictate tumour development.滑膜肉瘤:当表观遗传变化决定肿瘤发展时。
Swiss Med Wkly. 2018 Dec 2;148:w14667. doi: 10.4414/smw.2018.14667. eCollection 2018 Nov 19.
8
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.靶向降解 BRD9 可逆转滑膜肉瘤中的致癌基因表达。
Elife. 2018 Nov 15;7:e41305. doi: 10.7554/eLife.41305.
9
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.非典型 SWI/SNF 复合物是由 BAF 复合物扰动驱动的癌症的合成致死靶点。
Nat Cell Biol. 2018 Dec;20(12):1410-1420. doi: 10.1038/s41556-018-0221-1. Epub 2018 Nov 5.
10
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.SS18-SSX癌蛋白劫持KDM2B-PRC1.1以驱动滑膜肉瘤。
Cancer Cell. 2018 Aug 13;34(2):346-348. doi: 10.1016/j.ccell.2018.07.006.